Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery

Summary

This randomized phase II trial studies how well everolimus works in treating patients with pancreatic neuroendocrine tumors metastatic to the liver previously treated with surgery. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving everolimus after surgery may kill any tumors cells that remain.

Timeline

Start

2014-04-10

Primary completion

2017-07-19

Completion

2017-07-19

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual”

Drugs

Indications